Ken Griffin Arcellx, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$50.91 - $86.61 $524,373 - $892,083	10,300 Added 49.28%	31,200 $2.61 Million
Q2 2024 Aug 14, 2024	BUY	$49.74 - $66.98 $363,102 - $488,954	7,300 Added 53.68%	20,900 $1.15 Million
Q1 2024 May 15, 2024	SELL	$51.85 - $73.49 $979,965 - $1.39 Million	-18,900 Reduced 58.15%	13,600 $945,000
Q4 2023 Feb 14, 2024	BUY	$31.75 - $57.99 $904,875 - $1.65 Million	28,500 Added 712.5%	32,500 $1.8 Million
Q3 2023 Nov 14, 2023	SELL	$31.51 - $37.4 $88,228 - $104,720	-2,800 Reduced 41.18%	4,000 $143,000
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $74,223 - $126,630	2,700 Added 65.85%	6,800 $215,000
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $549,168 - $692,376	-20,400 Reduced 83.27%	4,100 $126,000
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $87,618 - $168,300	5,100 Added 26.29%	24,500 $759,000
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $323,398 - $427,576	19,400 New	19,400 $364,000

205

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.99B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.